Novavax (NVAX) has been one of our best performing stocks that has been trading in an accumulation range between $7 and $9. I believe that NVAX is trending for an upward breakout in Q4. The FDA has approved NVAX’s COVID vaccine for patient ages 12+, and the European Union is set to make a decision in October. I believe that NVAX has promising short-term outlook that will lead to a rally with a break above $9. So far $9.18 has been a key resistance target, but I believe that NVAX will ultimately break out to the light blue resistance level at $16.21

TradingView chart:
https://www.tradingview.com/chart/NVAX/sG5ojvU3-NVAX-Key-Price-Targets-After-10-Intraday-Rally/